Delivery Order SPE2DB22D1106-SPE2DB25FFAN1
- Not listed
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) on July 23, 2025, for the supply of Trulicity 1.5 mg/0.5 mL pens with a ceiling value of $1,858.72. This competitive award, issued without a set-aside designation, carries a firm fixed price structure with an ultimate completion date of July 24, 2025. The product will be performed and distributed from the contractor's location in Conshohocken, Pennsylvania. This delivery order represents a child...
- AmerisourceBergen Drug Corp was awarded a delivery order valued at $5,500.88 by the Defense Logistics Agency (DLA) on July 24, 2025, for the supply of Trulicity 1.5 mg/0.5 ml pens. This firm fixed-price delivery order is a non-set-aside contract with an ultimate completion date of July 25, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a continuation of AmerisourceBergen's role as a critical pharmaceutical supplier to the federal...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Trulicity 3 mg/0.5 mL pens valued at $1,993.08. This is a firm fixed-price delivery order with no set-aside designation, indicating the award was competitively procured. The delivery location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, with an ultimate completion date of July 31, 2025. This delivery order represents a child contract under...
- AmerisourceBergen Drug Corp was awarded a delivery order on July 25, 2025, by the Defense Logistics Agency for the supply of Trulicity 1.5 mg/0.5 mL pens with a ceiling value of $1,272.09. The contract employs firm fixed pricing and is not set-aside, indicating it was awarded through open competition. Performance will be completed at the company's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of July 28, 2025. This delivery order represents a child...
- AmerisourceBergen Drug Corp has been awarded a delivery order valued at $1,302.84 for Trulicity 1.5 mg/0.5 ml pens by the Defense Logistics Agency's Medical Supply Chain on July 24, 2025. This firm fixed-price contract is not set-aside and represents a single delivery of the diabetes medication to support military healthcare operations. The award is structured as a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Trulicity 3 mg/0.5 ml pens valued at $2,576.57. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded under AmerisourceBergen's existing contract vehicle. The product will be delivered to the company's distribution facility in Conshohocken, Pennsylvania, with an ultimate completion date of July 29, 2025. This delivery order represents a...
- The Defense Logistics Agency awarded a $26,572.45 delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Trulicity 3 mg/0.5 ml pens with an ultimate completion date of July 28, 2025. This competitive award, issued under firm fixed pricing with no set-aside designation, will be performed at the contractor's Conshohocken, Pennsylvania location. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency awarded a delivery order valued at $1,351.35 to AmerisourceBergen Drug Corp for Trulicity 0.75 mg/0.5 mL pens on July 28, 2025, with completion scheduled for July 29, 2025. This firm fixed-price delivery order, which was competitively awarded without set-aside designation, represents pharmaceutical procurement under the company's larger contract vehicle with DLA. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the...
- The Defense Logistics Agency awarded a delivery order valued at $1,801.80 to AmerisourceBergen Drug Corp for the supply of Trulicity 3 mg/0.5 mL pens on July 25, 2025, with completion scheduled for July 28, 2025. This competitively awarded, firm fixed-price delivery order represents a small-value pharmaceutical transaction under the company's broader supply arrangement with DLA. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency awarded a $5,756.58 delivery order to AmerisourceBergen Drug Corp for Trulicity 1.5 mg/0.5 mL pens on July 23, 2025, with completion scheduled for July 24, 2025. This firm fixed-price contract is a non-set-aside competitive award and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The pharmaceutical distributor, headquartered...
- SPE2DB22D1106Indefinite Delivery Contract
- SPE2DB22D1106-SPE2DB25FFAN1Delivery Order
AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) on July 30, 2025, for the supply of Trulicity 3 mg/0.5 mL pens valued at $1,553.26, with an ultimate completion date of July 31, 2025. This is a firm fixed-price, competitively awarded delivery order with no set-aside designation, to be performed at the company's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive $999,999,999.00 pharmaceutical prime vendor agreement running through December 2026 that supports military healthcare systems globally. AmerisourceBergen Drug Corp serves as a critical pharmaceutical distributor for federal medical procurement, particularly supporting the Defense Health Agency and military healthcare operations. The delivery order for Trulicity, a diabetes medication, exemplifies the company's role in supplying brand-name pharmaceuticals across multiple therapeutic domains through the DLA's Medical Supply Chain. The parent IDC contract reflects the company's capability to meet federal procurement requirements through open competition and positions it as a strategic vendor for the DLA's Pharmaceutical Prime Vendor Global Program, which anticipates multiple regional awards among several contractors to support worldwide military healthcare needs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.6k | 7/30/25 |